

Format for ANSWERING REVIEWERS

June 10, 2015



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 17942-edited 6Jun.doc).

Title: The position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome

Author: Abhasnee Sobhonslidsuk

Name of Journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS Manuscript NO: 17942

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) Reviewer 02860814

Comments To Authors	<p>1. The author has to refer to other causes of renal deterioration that have to be excluded in these patients</p> <p>Other causes of AKI were added (page 5)</p> <p>2. The author declares that terlipressin has a few side effects of cardiovascular events. However, everyday clinical practice provides us with different evidence.</p> <p>Incidence of cardiovascular events were added (page 8, ref 13)</p> <p>3. Superiority of terlipressin from other vasoconstrictor agents (midodrine plus octreotide) should be mentioned (Cavallin, Hepatology 2015).</p> <p>One ref (Cavallin, Hepatology 2015) was added with the statement of superiority of terlipressin over midodrine and octreotide plus albumin (page 8-9)</p> <p>4. It must be emphasized the need of early recognition/suspicion of this situation and the benefits from the timely and aggressive treatment, even without all the criteria for the diagnosis of HRS met.</p> <p>This information was added in CONCLUSION part. The role of renal</p>
---------------------	--

	biomarker is under investigation.
--	-----------------------------------

(2) Reviewer 02453015

Comments To Authors	<p>Major comments:</p> <ol style="list-style-type: none"> 1. English still needs to be improved. <p>A professional native English speaker proofread the paper. The edited certificate was submitted together with other revised documents.</p> <ol style="list-style-type: none"> 2. An early diagnosis of type 1 HRS is critical to the prognosis. Therefore, what are the criteria for achieving an early diagnosis? <p>This information was added in CONCLUSION part. The role of renal biomarkers is under investigation.</p> <ol style="list-style-type: none"> 3. Is there any way to start any therapy before reaching diagnostic criteria in order to get a better prognosis? <p>This information was added in CONCLUSION part.</p>
----------------------------	--


(3) Reviewer 00502973

Comments To Authors	<p>In this short review, Sobhonslidsuk et al. summarized the recent advances in the treatment of type 1 hepatorenal syndrome by vasoconstrictor and albumin infusion. It is relevant to the scope of the World Journal of Gastrointestinal Pharmacology and Therapeutics. The English is ok except a few of word expression. 1. "decompensate cirrhosis" change to "decompensated cirrhosis" 2. Page 6, 1st line from the bottom:"a consequence from impaired systolic and diastolic stimuli" change to "a consequence of impaired systolic and diastolic stimuli" 3. Page 7, Line 3:"TREATMENT FOR TYPE 1 HEPATORENAL SYNDROME (HRS)" change to "TREATMENT OF TYPE 1 HEPATORENAL SYNDROME (HRS)" It is acceptable for publication after minor language polish.</p> <p>Corrections were made according to reviewers' suggestion.</p>
----------------------------	--

3 References and typesetting were corrected

Thank you again for publishing our manuscript in *World Journal of Gastrointestinal Pharmacology and Therapeutics*.

Sincerely yours,



Abhasnee Sobhonslidsuk, MD.

Associate professor

Division of Gastroenterology and Hepatology

Ramathibodi Hospital,

270 Rama 6 road, Rajathevee, Bangkok 10400, THAILAND

Email: abhasnee.sob@mahidol.ac.th

Telephone: +66-02-201-1304

Fax: +66-02-201-1304